Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol

CAMBRIDGE, Mass. — Alkeus Pharmaceuticals, Inc. today announced the presentation of positive interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic for the duration of therapy ranging between two and six years. Results were presented during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9 in Seattle.

Learn More

Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Disease Patients During the ARVO 2024 Annual Meeting May 5-9

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. today announced that new positive data from its TEASE-3 clinical trial of gildeuretinol in teenage and young-adult patients with early-stage Stargardt disease will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9 in Seattle.

Learn More

Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc. today announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to six years. In its ongoing TEASE-3 clinical trial in early-stage Stargardt disease, the first three teenage patients enrolled in TEASE-3 and treated with oral gildeuretinol acetate remained asymptomatic and free of disease progression for their treatment duration ranging between two (one patient) and six years (two patients). In the absence of treatment, the patients were projected to begin experiencing vision loss within two years, following the same disease trajectory as that of their respective older siblings with identical genetic mutations who had not been treated with gildeuretinol.

Learn More